Company intelligence / Profile preview
Minka Therapeutics
Paris, Île-de-France, Franceminka-tx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
VAC-3S has demonstrated ability to produce anti-3S antibodies in 52% of patients treated in phase 1 and phase 2 clinical studies. Vaccine safety is confirmed in 131 patients treated in these studies[3].
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- VaccinesCAR-TCAR-NK
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Minka Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minka Therapeutics.